No access

Article

Published Online: September 1957

TWO-YEAR FATE STUDY OF THORAZINE-TREATED PATIENTS

PAUL E. FELDMANAuthors Info & Affiliations

Publication: American Journal of Psychiatry

Volume 114, Number 3

https://doi.org/10.1176/ajp.114.3.237

Get Access

Abstract

1. Ninety-six chronically psychotic patients (26.2%) treated over a 2-year period with Thorazine have been released from the hospital. The stability of the release is indicated by the fact that only 11 of these patients have been returned from parole.

2. Younger schizophrenics are more likely to respond to Thorazine to the extent that their release from the hospital is feasible.

3. Of the patients remaining in the hospital, 65.5% are still receiving Thorazine.

4. Behavioral improvement following Thorazine medication is maintained for at least 2 years.

5. There appears to be evidence that prolonged administration of Thorazine does not lead to tolerance formation. Eighty-five point four per cent of the patients are receiving identical or smaller dosages of Thorazine than they were receiving a year ago.

6. Some patients who responded minimally to Thorazine have shown a better response to one of the other tranquilizers.

7. Eighteen of the Thorazine patients are showing a better response to combined therapy.

8. Nursing personnel express conflicting opinions as to the efficacy of Thorazine medication.

9. There is ample evidence of continued toxicity of Thorazine after 2 years of medication. This reinforces the concept that ataractic therapy must at all times be under medical supervision.

10. Maintenence dosages are substantially smaller than the dosages necessary to obtain the initial therapeutic response.

11. Blood studies (at monthly intervals) must be continued so long as the patient receives Thorazine.

12. The need for routine liver-function tests is equivocal unless Thorazine medication is interrupted and then restarted.

13. Side effects persist throughout the period of medication. All of them can be controlled, ameliorated or eliminated by the administration of proper antidote or discontinuation of Thorazine medication.

Get full access to this article

View all available purchase options and get full access to this article.

Get Access

Information & Authors

Information

Published In

American Journal of Psychiatry

Volume 114 • Number 3 • September 1957

Pages: 237 - 240

PubMed: 13458482

History

Published in print: September 1957

Published online: 1 April 2006

Authors

Details

PAUL E. FELDMAN

Director of Research and Education, Topeka State Hospital, Topeka, Kan.

View all articles by this author

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format	RIS (ProCite, Reference Manager) EndNote BibTex Medlars RefWorks
Direct importt
Citation style
Style

Copy to clipboard
Tips for downloading citations

View Options

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR^® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

TWO-YEAR FATE STUDY OF THORAZINE-TREATED PATIENTS

Abstract

Get full access to this article